gracecastuc-038_lung_managing acq. resistance to egfr therapy (and probably crizotinib, too)
Published 11 years ago • 48 plays • Length 5:34Download video MP4
Download video MP3
Similar videos
-
28:22
gracecast-088_lung-cancer_challenging cases in lung cancer: acquired resistance to egfr tki therapy
-
29:24
gracecast-068_lung-cancer_sequist on acquired resistance to egfr
-
2:30
acquired resistance to osimertinib in egfr nsclc - 2022 program: targeted therapies forum - english
-
1:59:57
grace - global resource for advancing cancer education live stream
-
2:26
patterns of acquired resistance to egfr tkis in egfr mutation-positive nsclc
-
1:45
gracecastuc-034_lung_management strategies for acquired resistance to targeted therapies
-
3:07
third generation egfr tkis for acquired resistance
-
26:27
novel egfr inhibitors in the setting of acquired resistance
-
7:24
gracecastuc-025_lung_dr. riely on approach for acq. resistance to targeted therapies in adv. nsclc
-
1:59
gracecastuc-052_lung_juergens on managing acquired resistance to targeted therapies for adv. nsclc
-
14:43
gracecast-070_lung-cancer_q&a for acquired egfr tki and re-biopsying
-
1:01
dr. philip bonomi: gefitinib and later generations of egfr inhibitors
-
22:46
mechanisms of alk resistance & implications for treatment
-
13:00
stage 3a node-positive lung adenocarcinoma with alk rearrangement - case based panel discussions
-
2:22
aegean trial: perioperative durvalumab for nsclc - onctalk lung 2023
-
2:20
timing of second generation alk inhibitors: first line vs. treatment after acquired resistance
-
7:48
should avastin be added to egfr tki therapy for egfr mutation-positive nsclc?
-
3:43
how do you help your egfr patients make treatment decisions when their cancers grow?
-
1:12
gracecastuc-053_lung_will gains in targeted therapies be generalizable to a wider range of lc?